Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | |||
Cons | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 8/8 | |||
Category,Subcateogry | Equity,Sector - Healthcare | |||
Fund Age | 5 Years | |||
Fund Size | 755 Cr | |||
Min Investment | SIP ₹100 Lumpsum ₹1000 | |||
Expense Ratio | 1.1% | |||
Exit Load | 1% | |||
Benchmark Index | S&P BSE Healthcare PR |
No of Holdings | 29 | |||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (14.49%) Cipla Ltd (8.9%) Torrent Pharmaceuticals Ltd (7.6%) Abbott India Ltd (6.56%) Apollo Hospitals Enterprise Ltd (5.93%) | |||
No of Sectors | 2 | |||
Top 3 Sectors | Health (99.2%) Basic Materials (0.8%) | |||
Equity % | 98.62% | |||
Debt % | - | |||
P/E | 35.19 | |||
P/B | 5.89 | |||
Credit Quality | - | |||
Modified Duration | - | |||
YTM | - |
1-Month Return | 5.92% | |||
3-Month Return | -9.74% | |||
6-Month Return | -9.82% | |||
1-Year Return | 9.92% | |||
3-Year Return | 18.34% | |||
5-Year Return | 25.95% |
Sharpe | 0.74 | |||
Alpha | -0.56 | |||
Beta | 0.96 | |||
Standard Deviation | 16.88 | |||
Information Ratio | -0.34 |
Description | Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | |||
Managers | Dhaval Shah |